Clinical Trial Update: Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating time course of activity signs at high-frequency intravitreal ranibizumab for CNV due to age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Vista Klinik | Conditions: Choroidal Neovascularization, Age Related Macular Degeneration | Phase 4 | Status: COMPLETED